Aurinia soars on 629% EPS beat, raises 2026 guidance
Lupus nephritis drugmaker LUPKYNIS sales surge 25% as company issues optimistic growth outlook
Aurinia Pharmaceuticals delivered a stunning fourth-quarter performance that left analysts' estimates far behind, reporting earnings per share of $1.53 against expectations of just $0.21—a remarkable 629% beat that highlights the commercial success of its lupus nephritis treatment LUPKYNIS.
The Canadian biopharmaceutical company reported total revenue of $77.1 million for the quarter ended December 31, 2025, representing a 29% increase year-over-year. For the full year 2025, revenue reached $283.1 million, up 20% from $235.1 million in 2024, driven primarily by LUPKYNIS net product sales of $271.3 million—a 25% increase over the previous year.
The company's operating performance strengthened significantly in 2025, with cash flow from operating activities surging to $135.7 million from $44.4 million in 2024. Aurinia ended the year with a robust cash position of $398 million, providing substantial financial flexibility for advancing its pipeline and expanding commercial operations.
Building on this momentum, management issued 2026 guidance projecting LUPKYNIS net product sales between $305 million and $315 million, representing 12% to 16% growth at the midpoint. CEO Peter Greenleaf expressed confidence in the company's trajectory, noting that 2026 will focus on "increasing LUPKYNIS adoption and advancing aritinercept"—the company's dual BAFF/APRIL inhibitor pipeline asset currently under FDA review for B-cell mediated autoimmune diseases.
LUPKYNIS, the first oral therapy approved for active lupus nephritis, faces an increasingly competitive landscape that includes GSK's BENLYSTA and Roche's GAZYVA, which received US FDA approval for lupus nephritis in October 2025. Despite emerging competition, Aurinia has strengthened its market position as demand for lupus nephritis treatments continues to grow globally.
The company's pipeline received a boost in 2025 when aritinercept demonstrated positive Phase 1 results, showing significant reductions in immunoglobulins and a favorable safety profile. The asset is now under FDA review, with clinical studies in at least two autoimmune diseases planned for the second half of 2025.
Analyst sentiment surrounding Aurinia has shifted following the earnings release. Prior to the report, the consensus rating stood at "Hold" with an average price target of $17.25, though Jefferies had upgraded the stock to "Buy" with a $21 price objective in November 2025. Following the strong results, current analyst coverage shows 5 "Buy" ratings and 1 "Hold" rating, yielding a consensus "Buy" with a median price target of $14.17.
Despite the earnings beat, Aurinia shares experienced a modest decline in pre-market trading on February 26, slipping approximately 0.85% to $14.31 from the previous day's close of $14.43. The stock's muted reaction may reflect investor caution about looming competition, particularly as Maxxis Pharmaceuticals' generic voclosporin application was accepted by the FDA in February 2025, potentially threatening LUPKYNIS market share.
Looking ahead, investors will focus on two primary catalysts: LUPKYNIS's ability to maintain growth momentum amid increasing competition and progress on aritinercept's regulatory pathway. The company's strong cash position provides runway to navigate these challenges, while the aggressive 2026 guidance signals management's confidence in executing against commercial targets.
With a market capitalization of approximately $1.9 billion and trading at 26 times trailing earnings, Aurinia's valuation reflects the market's expectations for continued growth. The company's ability to meet or exceed the 12-16% sales growth target while advancing its pipeline will be critical to sustaining investor confidence throughout 2026.